Altimmune, Inc. (ALT) Stock Grade

About Altimmune, Inc.'s fundamentals

Altimmune is a biotechnology company with a market capitalization of $318.1 million that reported exceptional revenue growth of 105% year-over-year, indicating rapidly expanding business activity. However, the company is unprofitable, posting a significant net loss in its latest annual statement with a net margin of -214,861%, reflecting substantial operating expenses that far exceed revenue. The company does not currently pay a dividend, and traditional valuation metrics like P/E ratio and return on equity are not applicable due to the loss-making position. This profile is typical of early-stage biotech firms investing heavily in research and development while building toward profitability.